Montana passed SB535, a biotech law allowing physicians to administer experimental treatments outside trials if they completed FDA Phase 1, received approval from a state review board, and are delivered at licensed clinics with enhanced consent. The law uniquely permits sponsors and clinics to charge for treatment, addressing the "Valley of Death" funding gap where promising drugs stall between early trials and commercial investment.
Intercon Chemical Co. recalled six hand soap brands distributed across 15 U.S. states due to potential contamination with unspecified bacteria or antibiotic-resistant Pseudomonas and Serratia species. The affected products, sold under Laura Lynn, Summit, Vestis, and Intercon brands, may cause serious infections including blood infections, pneumonia, and urinary tract infections if used.